Minnesota-based Company to Present at Late Breaking Session during Congress of Neurological Surgeons
Contract med-tech manufacturer Minnetronix to launch own device
Minnetronix is developing a product that removes contaminants in the cerebral spinal fluid after a hemorrhagic stroke.
Feasibility of Neurapheresis™ Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
October 4, 2017 – Duke University Medical Center/Minnetronix Neuro Pseudomonas, Acinetobacter and Klebsiella are three multidrug resistant (MDR) gram-negative pathogens…
In Vitro Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
October 4, 2017 – Duke University Medical Center/Minnetronix Neuro Cryptococcal Meningitis is caused by Cryptococcus neoformans and is the most…
Minnetronix Maintains Perfect Record with Seventh FDA Inspection
Minnetronix, maintaining our perfect record, has now undergone seven successful FDA Quality System Inspection Technique (QSIT) inspections with No Action…
Let’s talk about Media opportunities.
Call 612-578-2834 or email beth@LaBreche.com
We are here to help